ATS: American Thoracic Society International Conference

Pulmonary rehabilitation boosts respiratory strength, the 6-minute walking test, and quality of life in children despite unchanged spirometry.

Twice-yearly depemokimab reduced exacerbations and improved quality-of-life outcomes in type 2 asthma and CRSwNP studies.

The American Thoracic Society 2026 International Conference included sessions that focused on topics such as pulmonary rehabilitation and global disparities in thoracic care.

ATS 2026 showcased new pulmonary therapies, clinical trials, and cross-specialty collaboration to improve patient care.

Jamie R. Felzer, MD, discusses vaccine misinformation, public mistrust, and strategies to restore confidence in this science.

Mark Metersky, MD, discussed heterogeneity, pathogens, and precision approaches in community-acquired pneumonia care.

Jamie R. Felzer, MD, discussed emerging vaccine strategies, preventive care, and translating evolving evidence into pulmonary practice at ATS 2026.

Yet Khor, MD, PhD, highlights diagnostic delays, language barriers, and inequities impacting ILD and PF care access.

New data examine switching biologics in severe asthma and inhaled treprostinil's effect on lung function in idiopathic pulmonary fibrosis (IPF).

Poster data show the efficacy of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis.

SUNRISE data showed tezepelumab improved asthma outcomes while reducing steroid dependence in severe asthma.

FVC percent predicted could differ in those with ILD who progress to terminal outcomes, indicating a need for patient monitoring.

Jerry A. Krishnan, MD, PhD, discusses NIH RECOVER findings on long COVID, pulmonary complications, and immune dysfunction at ATS 2026.

Chad Hochberg, MD, discussed how ICU learning health systems and predictive tools may improve critical care delivery.

SUNRISE trial data showed tezepelumab reduced oral steroid use while maintaining asthma control in severe asthma.

ALIS plus MDT improved symptoms and culture conversion in newly diagnosed MACLD, according to late-breaking data presented at ATS 2026.

PASSAGE trial data showed tezepelumab reduced asthma exacerbations in diverse and underrepresented patient populations, noted Njira L. Lugogo, MD.

ATS 2026 findings highlighted bleeding risks and hemodynamic responses with sotatercept in CTD-associated pulmonary arterial hypertension (PAH).

Early results show the potential for congestion pricing and clean air zones to be beneficial for the health of children in major cities.

RECOVER Initiative findings highlighted the heterogeneity of long COVID symptoms and mechanisms in diverse patient populations.

PASSAGE study data showed tezepelumab improved asthma outcomes across diverse, underrepresented patient populations.

Differences between sexes in cardiovascular health can appear as early as the neonatal stage in preterm infants.

Demetre Daskalakis, MD, MPH, Callen-Lorde, opened the first full day of ATS 2026 by highlighting the past, present, and future of vaccine policy in the US.

The conference, set to take place in Orlando, Florida, features sessions focusing on new research and environmental impacts in the thoracic space.

Marilyn Glassberg, MD, emphasizes the need for improved community education and highlights promising new drug pathways for idiopathic pulmonary fibrosis (IPF).

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those receiving placebo.

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, breaks down how to communicate the value of dupilumab using patient-centered language and sports metaphors to patients.

This study highlights the vital role of caregivers in supporting women living with pulmonary arterial hypertension (PAH) and underscores the need to enhance caregiver support and address unmet needs to improve patient outcomes.